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Aberrant antigens expressed by tumor cells, such as in melanoma, are often associated
with humoral immune responses, which may in turn influence tumor progression. Despite
recent data showing the central role of adaptive immune responses on cancer spread or
control, it remains poorly understood where and how tumor-derived antigen (TDA) induces
a humoral immune response in tumor-bearing hosts. Based on our observation of TDA
accumulation in B cell areas of lymph nodes (LNs) from melanoma patients, we developed
a pre-metastatic B16.F10 melanoma model expressing a fluorescent fusion protein, tan-
dem dimer tomato, as a surrogateTDA. Using intravital two-photon microscopy (2PM) and
whole-mount 3D LN imaging of tumor-draining LNs in immunocompetent mice, we report
an unexpectedly widespread accumulation ofTDA on follicular dendritic cells (FDCs), which
were dynamically scanned by circulating B cells. Furthermore, 2PM imaging identified
macrophages located in the subcapsular sinus of tumor-draining LNs to capture subcel-
lular TDA-containing particles arriving in afferent lymph. As a consequence, depletion of
macrophages or genetic ablation of B cells and FDCs resulted in dramatically reducedTDA
capture in tumor-draining LNs. In sum, we identified a major pathway for the induction of
humoral responses in a melanoma model, which may be exploitable to manipulate anti-TDA
antibody production during cancer immunotherapy.
Keywords: tumor-draining lymph node, tumor-derived antigen deposition, follicular dendritic cells, intravital
two-photon imaging, whole-organ imaging
INTRODUCTION
Melanoma, a potentially lethal skin cancer, is often associated with
the induction of humoral responses, which are typically inversely
correlated with the extent of the disease (1, 2). While some con-
troversy exists on whether anti-tumor-derived antigen (TDA) Ig
responses enhance or hamper tumor growth and metastasis (1–4),
there is renewed interest in investigating how interactions between
the adaptive immune system and cancer cells shape the spread
versus control of primary tumors (5–7). There are two major fac-
tors underlying this surge of interest: first, comprehensive patient
studies have shown that the presence of adaptive immune cells
in tumors positively correlates with a beneficial prognosis (8, 9).
As example, tumor infiltration of follicular helper T cells, which
are required for high affinity Ig production by germinal center
(GC) B cells, are associated with a good prognosis (10, 11). Simi-
larly, CD8+ T cell infiltration into breast tumors is associated with
survival when analyzed in more than 12,000 patients (12). Sec-
ond, preclinical and clinical studies have identified a promising
antitumoral efficacy by blocking immunosuppressive molecules
such as PD-1 and CTLA-4, which overrides inhibitory signals and
boosts host cytotoxic T cell responses against cancer cells (7, 13).
Importantly, a recent study has shown that antibodies directed
against both surface and cytoplasmic molecules contribute to effi-
cient CD8+ T cell responses by forming immune complexes that
are efficiently taken up by dendritic cells (DCs) for presentation
to cytotoxic T cells (14). In addition, antibodies directed against
intracellular tumor antigens are able to directly kill cancer cells
(15). Thus, anti-TDA Ig may exert multiple effects on tumor
control, beyond direct killing or antibody-dependent cytotoxicity.
Yet, there is surprisingly little information on how TDA induces
humoral responses. For example, it remains unclear whether
serum anti-TDA Ig levels observed in mouse cancer models and in
patients are exclusively initiated or maintained in tumor-draining
lymph nodes (TDLNs) or whether metastatic spread precipi-
tates such systemic responses. Furthermore, how TDA is actu-
ally collected by TDLNs is not well defined. Studies addressing
antimicrobial responses have analyzed the uptake of unprocessed
Ag, using as tools fluorescently labeled immune complexes, virus
particles, or other fluorescent cell populations, often in combi-
nation with intravital two-photon microscopy (2PM) (16). These
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findings have identified at least three pathways of Ag transport
to lymphoid tissue. First, B cells have been shown to become
directly activated by DCs that have migrated from the periph-
ery into draining lymphoid tissue and carry unprocessed Ag on
their surface (17). Second, low-sized lymph-borne Ag is directly
delivered to follicular dendritic cells (FDCs) via a conduit sys-
tem formed by stromal cells of the lymph node (LN) interstitium
(18). FDCs are arguably the most important antigen-presenting
cells for naïve B cells and play a central role for the establishment
and maintenance of GC reactions, which enhance the affinity of
mAbs through somatic hypermutation and selection of suitable
clones (19). Third, lymph-borne antigens including virus par-
ticles are captured by macrophages located in the subcapsular
sinus (SCS), which are equipped with scavenging receptors such
as lectins (20–22). In this context, it is interesting to note that
CD169+ SCS macrophages also mediate the uptake of TDA from
apoptotic tumor cells, which they then process for presentation
on peptide–MHC complexes. This leads to T cell activation and
subsequent tumor elimination (23). In addition, SIGN-R1+ DC
subsets located in the LN medulla participate in the capture of
specific virus particles arriving in afferent lymph (24). These cells
then relay captured antigen to B cell follicles, and when present
as immune complexes, non-specific B cells act as transporters for
final deposition on FDCs (25).
Yet,which of these multiple pathways is engaged in TDA capture
and relay to FDCs for B cell activation remains little investi-
gated. This is in large part owing to a lack of precise detection
and quantification methods of unprocessed TDA in commonly
used immunohistological analysis. Based on the successful adop-
tion of intravital 2PM in observing and quantifying the uptake
of fluorescent viral particles and immune complexes in reactive
LNs (16), we set out to perform similar experiments in TDLNs,
using a B16.F10 melanoma model expressing the fusion protein
tandem dimer tomato (tdTom) as a surrogate TDA for use in fluo-
rescent imaging (26, 27). We combined dynamic time-lapse 2PM
imaging with stereomicroscopy and quantitative optical projec-
tion tomography (OPT) of whole-mount TDLNs. OPT is based
on reconstruction of back-projected images to form 3D images
and has proven a useful tool for isotropic imaging and quantifi-
cation of B cell follicles and vascular networks in LNs (28). We
found that systemic anti-TDA IgG responses correlated with an
unexpectedly widespread distribution of TDA in the vast majority
of FDC networks of TDLNs, and also in part in further drain-
ing LNs but not in non-draining LNs. Furthermore, we show that
SCS macrophages are required for the rapid uptake of subcellular-
sized tdTom+ TDA, from where it is transported to FDCs for
extensive screening by B cells. In sum, we propose a mechanism of
how TDA is processed in TDLNs to induce local B cell responses
that lead to systemic IgG levels. Furthermore, this is to the best
of our knowledge the first study providing a quantitative assess-
ment of Ag deposition in whole-mount lymphoid tissue using 3D
reconstructions.
MATERIALS AND METHODS
MICE
Four to 6-week-old female C57BL/6 mice were purchased from
Janvier (AD Horst, Netherlands). Igh-Jtm1Cgn B cell-deficient
(JHT) mice (29) and C57BL/6-Tg(CAG-EGFP)1Osb/J ubiq-
uitously GFP-expressing mice were obtained from the Insti-
tut für Labortierkunde, University of Zürich, Switzerland.
Tg(IghelMD4)4Ccg BCR-transgenic (30) mice on a RAG−/− back-
ground (MD4) were kindly provided by Emilie Jacque, NIMR,
London, UK. CX3CR1tm1Litt fractalkine receptor-heterozygous
(CX3CR1+/gfp) mice (31) were kindly provided by Prof. Richard
Ransohoff (Lerner Research Institute, Cleveland, OH, USA). All
mice were kept under SPF conditions at the Central Animal facil-
ity at the Department for Clinical Research and the Theodor
Kocher Institute, University of Bern. All animal work has been
approved by the Cantonal Committee for Animal Experimentation
and conducted according to federal and cantonal guidelines.
ANTIBODIES AND REAGENTS
APC-conjugated anti-Ly6C (HK1.4) and PerCP-conjugated anti
CD11b (M1/70) were from Biolegend. Purified anti-mouse-LYVE-
1 was purchased from R&D. Purified anti-CD35 mAbs (7G6) was
purchased from BD Biosciences. Anti-PNAd mAb (MECA-79)
was affinity purified from hybridoma supernatant (Nanotools).
All mAbs were fluorescently conjugated using AlexaFluor pro-
tein labeling kits (Molecular Probes, Invitrogen). CellTracker Blue
(CMAC) fluorescent dye for cell labeling was also purchased from
Molecular Probes.
TUMOR CELL LINE AND INDUCTION OF s.c. TUMORS
We have previously described the stable murine melanoma cell
line B16.F10-tdTom expressing a fusion protein of SNAP-tag and
tdTomato red fluorescent protein and coexpressing luciferase (27).
Single B16.F10-tdTom stable clones were isolated by limiting dilu-
tion and tdTomato expression was analyzed by flow cytometry
(FACScalibur, BD Bioscience). Aliquots were frozen and stored in
liquid nitrogen to avoid maintaining the cell line in culture with
high passage numbers. Before each tumor injection experiment, a
fresh aliquot of cells was thawed and cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) (Invitrogen) containing 10% fetal
calf serum (FCS) and 1.2 mg/ml G418 (Invitrogen). tdTomato flu-
orescent intensity was verified each time by flow cytometry before
in vivo injection. Adult mice (6–8 weeks) received s.c. injections of
2× 105 B16.F10-tdTom cells in 10µl to trigger tumor formation
in the right footpad. Tumor growth was observed over a period of
up to 30 days and where indicated observed under a stereomicro-
scope setup equipped with a fluorescent light source and a CCD
camera (Leica MZ16; filters: GFP excitation 480/40 nm, emission
510; Cy3 excitation 560/40 nm, emission 605). In some experi-
ments, we injected 20µl of B16.F10-tdTom tumor lysate (107 cells
sonicated in 1 ml of 15 mM carbonate buffer, pH 9.6, at constant
cycles for 15 s) in the right footpad. For macrophage depletion,
mice were treated with control liposomes or CLL (2 mg in 200µl
PBS) i.p. 24 h after tumor cell injection in the footpad, and then
treated every 2 days with 1 mg of control liposomes or CLL i.p. for
15 days.
ELISA FOR DETECTION OF ANTI-TDA IgG
Serum of control mice and mice bearing B16.F10-tdTom tumors
were collected for IgG titration. In brief, NuncTM 96-Well plates
were plated with 100µl of B16.F10-tdTom lysate diluted 1:25–
1:78125 o.n. at 4°C. After washing with washing buffer (WB;
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PBS/0.05% Tween20) (Sigma-Aldrich), plates were incubated with
300µl WB/5% dry milk for 2 h at RT. Serum dilutions (100µl/well
in 1:5 steps) were added and incubated for 2 h at 37°C. After
washing with WB, biotinylated polyclonal goat anti-mouse IgG
(10 ng/well; AbD Serotec) diluted in WB was added for 1 h at
RT. Wells were washed and incubated for 1 h at RT with 100µl
streptavidin-HRP (AbD Serotec) diluted 1/1000 in WB. Bound
antibodies were detected using OPD substrate, and absorbance was
read at a wavelength of 490 nm. Results were calculated as titer by
interpolation of absorbance values at a fixed serum dilution into a
linear regression analysis plotting.
2PM OF POPLITEAL PLNs
Where indicated, B cells were isolated from C57BL/6 mice using
magnetic bead sorting (EasyStep negative isolation Kit, STEM-
CELL Technologies; purity of >95%) and labeled with CMAC as
described (32). Labeled B cells (5× 106 cells/mouse) were injected
i.v. into sex-matched tumor-bearing recipient mice 24 h before
2PM imaging. Mice were surgically prepared as described (33). In
brief, mice were anesthetized by i.p. injection of physiologic saline
solution containing xylazine (10 mg/kg) and ketamine (50 mg/kg).
After shaving and fixation of the right hind leg, the tumor-draining
popliteal LN was carefully exteriorized without directly touching
it, and kept moist with saline. 2PM imaging was performed using
the TrimScope system equipped with a 20× objective (NA 0.95)
(LaVision Biotec, Germany) and a Ti:Sapphire NIR laser (MaiTai,
Spectraphysics) tuned to 780 or 840 nm. For four-dimensional
analysis of cell migration, 10–18 z-stacks (spacing 2–4µm) of
200–300µm× 200–300µm x–y sections were acquired every
20 s for 20 min. HEVs and blood vessels were identified by 10–
15µg AlexaFluor633-conjugated MECA-79 or Dextran Cascade
blue (10 kDa, Molecular probes; 50µl of 20 mg/ml stock solution
per mouse) injected i.v. prior to 2PM observations. Alexa488-
conjugated anti-LYVE-1 (0.1 mg/ml; Clone 223322, R&D sys-
tems) was s.c. injected into footpads in a volume of 20µl 12 h
prior to imaging. Sequences of image stacks were transformed
into volume-rendered four-dimensional movies using Volocity or
Imaris software, which was also used for semiautomated track-
ing of cell motility in three dimensions. For instantaneous 3D
velocity and turning angle calculations, we used MatLab scripts as
described (34).
OPTICAL PROJECTION TOMOGRAPHY OF CONTROL AND
TUMOR-DRAINING LNs
Where indicated, GFP-expressing B cells from LNs and spleen
were purified by negative immunomagnetic cell sorting and trans-
ferred i.v. into tumor-bearing recipient mice 1 day before PLN
excision (2× 107/mouse). Excised LNs were carefully cleaned of
surrounding fat, fixed in 4% ultrapure paraformaldehyde (Elec-
tron Microscopy Sciences, Hatfield, PA, USA) for 4 h at 4°C and
then washed in PBS. LNs were embedded in 2% ultrapure agarose
(Invitrogen) and incubated for 2 weeks in ScaleU2 solution (4 M
urea, 30% glycerol, 0.1% Triton-X, pH 7.7), which preserves
fluorescent protein signals (35). OPT scanning was performed
according to the manufacturer’s instructions (Bioptonics). Filter
sets were exciter 425/40, emitter LP475 for autofluorescent sig-
nal, exciter 480/20, emitter LP515 for green fluorescent signal and
exciter 545/30, emitter 617/75 for red fluorescent signal. Raw data
were converted into 3D voxel datasets using NRecon software from
Bioptonics. Reconstructed virtual xyz data sets were exported as
.TIFF or .bmp files and analyzed with IMARIS (Bitplane) for iso-
surface calculation of total LN volume and other parameters as
described (28). IMARIS reconstructions were carefully adjusted
to fit original NRecon reconstructions.
IMMUNOFLUORESCENCE OF MOUSE PLNs
Contralateral and tumor-draining popliteal and inguinal LNs were
removed, embedded in Tissue-tek (OCT compound, Syxmex Dig-
itana) and snap-frozen in an isopentane bath (2-Methylbutane,
Grogg Chemie) at −80°C. Cryostat sections (10µm) were air-
dried overnight before staining. Sections were fixed for 15 min
with 1% paraformaldehyde at RT. After blocking with blocking
buffer [5% skimmed milk (w/v), 0.3% Triton X-100 (v/v), and
0.04% (w/v) NaN3 in TBS], sections were incubated for 1 h at room
temperature with the primary antibody diluted in PBS/1% FCS.
Secondary antibodies were diluted in PBS/1% FCS and sections
incubated for 1 h at room temperature before mounting in Mowiol
(Calbiochem). Samples were analyzed using a Nikon Eclipse E600
microscope (Nikon Instruments) equipped with a Nikon Digital
Camera (DXM1200F or DS-Ri1; Nikon Instruments). Images were
processed with NIS Elements Version 3.2 software.
IMMUNOFLUORESCENCE OF HUMAN LYMPH NODE SAMPLES
The study was approved by the Medical Ethics Committee of the
Canton of Bern, Switzerland. Formalin-fixed LN tissue samples
were obtained from patients with primary cutaneous melanoma
(Brelsow index >1 mm) who underwent diagnostic sentinel
LN biopsy. About 3µm-thick paraffin-embedded sections were
dewaxed, rehydrated, and pretreated as described previously (36).
Tissue sections were serially incubated with a rabbit anti-human
Melan A antibody (Novus, 110-57185) followed by incubation
with a AlexaFluor594-labeled goat anti-rabbit F(ab′)2 (Invitro-
gen, A11072). Sections were then incubated with mouse-anti-
human CD20 (Biosystem, PA0906) specific for naïve, memory,
and GC B cells, followed by isotype-specific AlexaFluor488 goat
anti-mouse IgG1 (Invitrogen, A-21121). Finally, cells were stained
with diamidino-phenylindol nucleic acid stain (D1306; Invitrogen,
Carlsbad, CA).
STATISTICAL METHODS
Data were analyzed with GraphPad Prism 6 using a Kruskal–Wallis
test with Dunn’s multiple comparison test. Significance was set at
p< 0.05.
RESULTS
IMMUNOFLUORESCENT ANALYSIS OF MelA CO-LOCALIZATION WITH B
CELLS IN HUMAN TDLN SECTIONS
To establish whether TDA deposition is observed in human lym-
phoid tissue, we analyzed paraffin TDLN sections of human
melanoma patients by immunofluorescent staining, focusing on
MelA as model melanoma antigen. To identify B cell follicles, we
labeled B cells directly using anti-CD20 mAb. While MelA staining
readily identified metastasizing tumor cells (Figure S1 in Supple-
mentary Material), we found that this antigen was variably co-
localizing with B cells. Thus, while in some cases no co-localization
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of anti-CD20 and MelA signal was observed (Figure S1A in Sup-
plementary Material), we found in other cases the presence of
non-tumor cell associated MelA in B cell follicles (Figures S1B,C
in Supplementary Material). Thus, TDA deposition is found in
human TDLNs, where it is likely to contribute to the anti-IgG
response observed in melanoma patients.
ESTABLISHING A LOCAL TUMOR MODEL LEADING TO ANTI-TDA IgG
RESPONSES IN IMMUNOCOMPETENT MICE
Based on the observations made in human TDLNs, we set out to
identify the mechanisms of TDA deposition using as melanoma
model B16.F10 cells expressing high levels of a cytoplasmic tandem
dimer Tomato fusion protein (B16.F10-tdTom) (27) (Figure 1A).
Thirty days post s.c. injection into the footpad of immunocom-
petent C57BL/6 mice, we observed a bright red fluorescent signal
in the footpad that had received B16.F10-tdTom cells, but not the
contralateral footpad (Figure 1B). At this time point, we failed to
detect fluorescent signals in lung, liver, kidney, and spleen, indi-
cating that the primary tumor had not yet spread to other organs
(not shown). Next, we investigated whether local tumor growth
was sufficient to induce the generation of anti-tumor IgG produc-
tion. We established an ELISA against B16.F10-tdTom melanoma
cell lysate using an anti-tdTom+ mAb as positive control (not
shown) before testing control and B16.F10-tdTom-tumor-bearing
mice for the presence of anti-TDA mAbs in serum. At 30 days post
B16.F10-tdTom injection, we readily detected significant titers of
anti-B16.F10-tdTom IgG mAbs in tumor-bearing but not mock-
injected mice (Figure 1C). In contrast, B16.F10-tdTom lysate
injection 15 days post tumor implantation had only a minor,
non-significant effect on anti-TDA IgG responses. In sum, we
established a pre-metastatic local tumor model, which leads to
robust anti-TDA IgG responses.
LIVE IMAGING OF tdTom+ TDA DEPOSITION ON FDCs IN TDLNs
The strong IgG response in metastatic-free tumor-bearing mice
prompted us to investigate in detail the accumulation of TDA in
TDLNs. To this end, we examined the deposition of fluorescent
tdTom+ structures as surrogate TDA 30 days post tumor injec-
tion, using 2PM and immunofluorescence of TDLN sections. In
some experiments, we co-transferred fluorescently labeled B cells,
and stained lymphatic and blood vasculature with appropriate
fluorescent markers (Figure S2A in Supplementary Material). 3D
reconstructions of 2PM image sequences of TDLNs performed in
live, anesthetized mice showed that in the SCS, tdTom+ structures
were found closely associated with LYVE-1+ structures, which
represent both lymphatic endothelial cells and macrophage sub-
sets (Figure 2A, arrow). Strikingly, we also found tdTom+ signals
below the SCS not co-localizing with LYVE-1 (Figure 2A, arrow-
head and Movie S1 in Supplementary Material). Using anti-PNAd
mAbs and fluorescent dextran as markers for HEVs and blood
vessels, respectively, we found that tdTom+ structures were exclu-
sively found in regions that did not contain HEVs (Figure 2B)
but were transversed by extensive capillary networks (not shown).
High-resolution 2PM image sequences uncovered that tdTom+
structures showed a dendritic morphology but did not undergo
cell displacement, despite occasional shape changes of their den-
drites (Figure 2B; Movies S1 and S2 in Supplementary Material).
Based on their morphology and localization within TDLNs, we
hypothesized that tdTom+ TDA is deposited on or endocytosed
by FDC (37). This was indeed the case, since we found an almost
complete overlap of tdTom+ with the FDC-marker CD35 inside
B cell follicles (Figure 2C). Taken together, we found that tdTom+
TDA becomes closely associated with FDCs in TDLNs.
EXTENSIVE SCANNING OF tdTom+ FDCs BY B CELLS
Naïve B cells continuously migrate to B cell follicles, where they
extensively scan the FDC network for presence of cognate Ag.
In 2PM studies of TDLNs, we confirmed frequent interactions of
adoptively transferred naïve B cells with tdTom+ FDCs (Figure 3A;
Movies S3 and S4 in Supplementary Material). While some B
cells were occasionally observed to arrest for a few minutes on
such structures (see example in Figure 3A), most B cells showed
robust motility as assessed by their track lengths (Figure 3B).
Furthermore, B cells speeds (8.46± 2.52µm/min; mean± SD)
(Figure 3C), turning angle distribution (Figure 3D), and their
motility coefficient (16.7µm2/min) in TDLNs were in the range
of values obtained in non-tumor-draining resting LNs (32, 38–41).
Taken together, our 2PM analysis uncovered extensive scanning of
FIGURE 1 | Local melanoma tumors generate systemic circulating IgG
levels. (A). Outline of local tumor injection experiment. B16.F10-tdTom+ cells
were s.c. injected into C57BL/6 mice on day 0 and allowed to proliferate for
30 days. In some mice, B16.F10-tdTom lysate was additionally s.c. injected to
test whether IgG production can be boosted. (B) Brightfield (top) and red
fluorescent (bottom) stereomicroscopic images of tumor-injected and
contralateral footpads on day 30. (C) IgG titers in control and tumor-bearing
mice on day 30, with and without additional B16.F10-tdTom+ cell lysate
injection for 15 days. Each dot represents the serum of one mouse. Data in
(C) are pooled from two independent experiments and were analyzed by a
Kruskal–Wallis test with Dunn’s multiple comparison test. **p<0.01,
***p<0.001.
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FIGURE 2 | Co-localization of tdTom+ signal with FDCs inTDLNs.
B16.F10-tdTom+ cells were s.c. injected into C57BL/6 mice on day 0 and
allowed to proliferate for 30 days. Anti-LYVE-1 mAb was injected s.c. one day
before 2PM analysis, while anti-PNAd (MECA-79) mAb was injected i.v. on
the day of the 2PM experiment. (A) 2PM projection showing intranodal
localization of tdTom+ signals (arrowhead) below the SCS region after LYVE-1
labeling. The arrow shows the outer capsule. Scale bar, 50µm. (B) 2PM
projection showing close proximity of tdTom+ structures with macrophages
identified by autofluorescent signal and in regions that do not contain HEVs of
the T cell area. The time-lapse sequence shows the dendrite-like shape of
tdTom+ structures (arrowheads). Scale bar, 50µm, time in minutes and
seconds. (C) Immunofluorescent PLN section showing overlap of tdTom+
signals with the FDC-marker CD35 inside B cell follicles identified by B220
staining. Scale bars, 100µm (top) and 20µm (bottom).
TDA by circulating naïve B cells, which is a prerequisite for the
encounter of cognate Ag and the initiation of a humoral immune
response.
WHOLE-MOUNT ORGAN ANALYSIS UNCOVERS WIDESPREAD tdTom+
TDA DEPOSITION ON FDCs OF TUMOR-DRAINING BUT NOT
NON-DRAINING LNs
In our live 2PM experiments, we observed a remarkably close
association of TDA with FDCs. To gain a more comprehensive
overview on TDA deposition in tumor-draining and non-draining
LNs in a larger field of view than possible by 2PM, we iso-
lated whole TDLN and non-draining LNs of mice, which had
in addition received s.c. injections of the FDC-marker anti-CD35
mAb as tracer for fluorescent stereomicroscopic analysis (Figure
S2B in Supplementary Material). In line with primary tumor
growth in the footpad, we observed a strong tdTom+ signal in
popliteal TDLNs, which colocalized with the anti-CD35+ signal
(Figure 4A). In ipsilateral inguinal LNs, we observed a weaker
tdTom+ signal co-localizing with CD35+ FDCs, which was present
in some LNs in one hemisphere only, presumably because this
hemisphere may have received lymph from other LNs downstream
of TDLNs or directly from the footpad (42) (Figure 4B). In some
experiments, we found tdTom+ signal in both hemispheres of
ipsilateral inguinal LNs, but always in lower amounts than in
the primary popliteal TDLN (not shown). In contrast, the non-
draining brachial LN showed weak to no anti-CD35+ or tdTom+
signal (Figure 4C). Thus,our anti-CD35+mAb tracer experiments
mimic to a large extent the path followed by the surrogate tdTom
TDA and suggest that the route of lymphatic drainage determines
the location of TDA accumulation.
Since stereomicroscopic images showed qualitatively a wide-
spread distribution of fluorescent TDA, we applied emission OPT
to draining and non-draining LNs of mice, which had received
s.c. B16.F10-tdTom injections in the right footpad, for a com-
prehensive assessment of tdTom+ signal frequency and distri-
bution in entire organs (Figure 4D; Movie S5 in Supplemen-
tary Material) (28). When we analyzed the volume of TDLNs
(Figure 4E), as well as the number and total volume of tdTom+
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FIGURE 3 | Dynamic B cell behavior onTDA-coated FDCs. (A) 2PM
image sequence showing B cell migration along tdTom+ structures
31–95µm below the TDLN capsule in CX3CR1+/gfp recipients. A
representative B cell track is shown as dotted line. Scale bar, 10µm;
time in minutes and seconds. (B) Representative tracks (>10 time
points) of B cells migrating taken from the image sequence shown in
A. One square corresponds to 11.2µm. (C) Quantification of B cell
speeds in TDLNs. (D) Quantification of turning angles of B cells in
TDLNs. Data in (A–D) are from three mice in one experiment, with 433
B cell tracks analyzed.
structures (Figures 4F,G), we found that tdTom+ structures occu-
pied approximately 3.6% of the total TDLN volume distributed in
approximately 20 locations per LN. Since our previous OPT analy-
sis had determined that B cell follicles occupy approximately 10%
of the total LN volume (28), and based on the observation that
FDC occupy only the central part of B cell follicles, our data indi-
cate that tdTom+ is deposited in most B cell follicles. To address
this point directly, we adoptively transferred GFP+ B cells as mark-
ers for B cell follicles and repeated our OPT analysis (Figure 4H).
As predicted, we observed a widespread tdTom+ signal distribu-
tion in the FDC-containing center of 84 and 90% of B cell follicles
in two TDLNs (Figure 4I). Thus, at 4 weeks post s.c. B16.F10-
tdTom injection, TDA occupied a large proportion of B cell follicles
in TDLNs, providing an explanation for the high IgG titers found
in serum 30 days after B16.F10-tdTom injection (Figure 1C). To
the best of our knowledge, this analysis constitutes the first quan-
titative approach to assess antigen deposition on FDC, not only in
cancer research but also more generally in the field of immunology.
2PM IMAGING UNCOVERS THAT CX3CR1+ SCS MACROPHAGES
COLOCALIZE WITH AND TAKE UP SUBCELLULAR-SIZED tdTom+
PARTICLES ARRIVING IN AFFERENT LYMPH
We next investigated the cellular mechanism of TDA capture
in TDLN. Since SCS macrophages have been implicated in the
uptake of apoptotic EG7 T cell thymoma tumor cells for pre-
sentation to T cells (23), we asked whether a similar process
takes place in PLN draining s.c. injected B16.F10 melanoma cells.
We surgically prepared TDLNs of CX3CR1+/gfp mice, in which
SCS macrophages are expressing GFP, for direct in vivo 2PM
imaging 9–14 days post B16.F10-tdTom injection, when primary
tumors became palpable in the footpad (Figure 5A; Figure S2A
in Supplementary Material). We observed tdTom+ vesicles of
subcellular size (<5µm diameter) just below the collagen fibers
of the LN capsule. These tdTom+ structures were typically in
close apposition to or inside of CX3CR1+ macrophages in the
SCS of the tumor-draining popliteal LNs (Figure 5A; Movie S6
in Supplementary Material). To verify that tdTom+ signal was
indeed associated with macrophages, we used flow cytometry and
identified a fraction of CD11b+ Ly6C+ macrophages that con-
tained tdTom+ material in TDLNs but not in contralateral LNs
(Figure 5B). Our data thus support a role for CX3CR1+ SCS
macrophages in the uptake of subcellular-sized tumor-derived
material presumably from apoptotic tumor cells, in line with
previous observations (23).
tdTom+ TDA DEPOSITION IN TDLNs IS ABOLISHED IN THE ABSENCE OF
MACROPHAGES, B CELLS OR FDCs
Based on our observation of macrophage-mediated uptake of
tdTom+ TDA, we used clodronate liposomes (CLL) or empty lipo-
somes as controls to deplete macrophages systemically (Figure S2C
in Supplementary Material). As predicted, CLL treatment abol-
ished CD11bhigh CD169high macrophages in TDLNs to a large
extent (Figure 5C). In parallel, we observed a strong decrease
in tdTom+ TDA accumulation on FDCs of CLL but not control
liposome-treated TDLNs (Figures 5D,E), supporting our intrav-
ital microscopy data that macrophages capture TDA arriving in
afferent lymph. These data further suggest that other cell types
such as migratory DCs cannot compensate for macrophages to
deliver TDA to TDLNs.
Next, we investigated the efficacy of tdTom+ TDA deposition
in TDLNs of JHT mice with defective B cell formation (43). In
addition to lacking B cells, JHT mice do not develop FDCs, which
allowed us to assess the function of these cells for TDA retention.
Despite growth of B16.F10 tumor at the primary injection site
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FIGURE 4 |Whole-mount analysis of tdTom+ spread inTDLN and
non-TDLN. B16.F10-tdTom+ cells were s.c. injected into C57BL/6 mice on
day 0 and allowed to proliferate for 15 days. On day 14, Alexa488-labeled
anti-CD35 mAb was injected s.c. into the same footpad to label FDCs.
(A) Representative green (left) and red (right) fluorescent image of primary
TDLN (popliteal LN). An overlay is shown in the right panel, with overlapping
signal indicated by arrowheads. (B) Representative green (left) and red (right)
fluorescent image of inguinal LN from the ipsilateral tumor side. An overlay is
shown in the right panel, with overlapping signal indicated by arrowheads.
(C) Representative green (left) and red (right) fluorescent image of
non-draining brachial LN. An overlay is shown in the right panel. (D) Examples
of 3D reconstructed OPT-derived autofluorescent and tdTom+ signals from
popliteal and inguinal LNs. Scale bar, 400µm. (E) Quantification of total TDLN
volumes. Each dot represents one LN. (F) Number of tdTom+ structures per
TDLN. (G) Quantification of total volume of tdTom+ structures per TDLN.
(H) Ex vivo stereomicroscopic images of isolated TDLNs after transfer of
GFP+ B cells 24 h before excision to identify B cell follicles. (I) Quantification
of tdTom+ B cell follicles over total number of B cell follicles in two
representative TDLNs. Each square in (A–C) represents 1 mm2. Data in
(A–C) are representative of from 10 mice from 4 independent experiments,
while data in (D–I) are representative for 3 mice from 3 independent
experiments, with a total of 5 LNs analyzed.
in the footpad (not shown), we were unable to detect tdTom+
signal in TDLNs of JHT mice 15–30 days post tumor injection
(Figure 5F). Similar results were obtained in MD4 BCR x RAG−/−
transgenic mice, in which B cells are restricted to a single speci-
ficity of antibodies. While the lack of T cells resulted in smaller LN
size, no tdTom+ signal was detected despite normal primary tumor
growth in footpad (Figure 5G). Taken together, the lack of tdTom+
signals in macrophage-depleted or B cell- and FDC-deficient
TDLNs suggests that the majority of tdTom+ signal is indeed
taken up by macrophages and becomes associated with FDCs,
although we cannot exclude occasional metastatic B16.F10-tdTom
cells contributing to red fluorescent signal in TDLNs.
DISCUSSION
Lymph nodes filter afferent lymph for the presence of noxious
particles to prevent their systemic spread and for presentation
of antigen to passing lymphocytes. In the present study, we
combined 2PM and OPT imaging to dissect the mechanism by
which unprocessed, or incompletely processed, TDA accumu-
lates in TDLNs. To this end, we took advantage of an intrinsi-
cally fluorescent surrogate TDA as a tool to examine its spread
in secondary lymphoid organs, following previously established
protocols investigating fluorescently labeled virus particle uptake
(16). We report two major findings: first, TDA is efficiently cap-
tured by TDLNs and to a minor extent by further downstream LNs
for an unexpectedly widespread distribution on most FDC net-
works. Second, we were able to correlate this finding with intravital
imaging of SCS macrophage association with subcellular-sized
TDA+ particles. Macrophage depletion abolished TDA uptake in
TDLNs, providing strong support that SCS macrophages, rather
than migratory DCs or passive diffusion, are required for efficient
capture of tumor-derived particles in our model.
While confocal and multiphoton microscopy have become cen-
tral tools for studying metastazing cancer cells and interactions
with infiltrating lymphocytes (44–47), the present study represents
to the best of our knowledge the first attempt to exploit fluorescent
imaging to comprehensively examine TDA deposition in draining
LNs. While in our mouse model, we at first suspected that tdTom+
signals in TDLNs stemmed directly from metastasizing B16.F10-
tdTom melanoma cells, as described in models of i.v. injected
GFP-expressing melanoma cells (48), several lines of evidence
suggested that this signal derived from TDA: first, we observed
macrophage capture of presumably apoptotic subcellular tdTom+
fragments, with subsequent accumulation on FDC. Second, at later
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FIGURE 5 | tdTom+ particle capture by SCS macrophages correlates
withTDA deposition on FDCs. B16.F10-tdTom+ cells were s.c. injected
into CX3CR1+/gfp, JHT or MD4 mice for 2PM and stereomicroscopy analysis.
(A) 2PM image sequence of CX3CR1+/gfp macrophages associating with
subcellular-sized tdTom+ particles (arrows) in TDLN SCS on day 9 after tumor
injection. Free tdTom+ particles are marked with an arrowhead. SHG,
second harmonic generation image of collagen fibers in capsule. Scale bar,
20µm; time in minutes and seconds. (B) Flow cytometry of CD11b+ Ly6C+
FCShigh macrophages for tdTom signal in TDLN and contralateral LN.
(C) Representative flow cytometry analysis of popliteal TDLNs after control
liposome or CLL treatment. (D) Representative green (left) and red (right)
fluorescent image of primary TDLN (popliteal LN) in control liposome-treated
mice on day 15 post tumor injection. Arrowheads in the overlay (right) point
to tdTom+ signals. (E) Representative green (left) and red (right) fluorescent
image of primaryTDLN (popliteal LN) in CLL-treated mice. (F) Representative
brightfield (left), and red fluorescent (right) image of popliteal and inguinal
TDLN in B cell-deficient JHT mice. (G) Representative brightfield (left), and
red fluorescent (right) image of inguinal and popliteal TDLN in MD4 mice.
Each square in F represents 1 mm2. Data in (A) are representative of four
mice in two independent experiments, while B is showing results of one of
two mice. Data in (C–G) are representative of 3 CLL- and 2 control
liposome-treated C57BL/6 mice in one experiment, and 7 JHT and 5 MD4
mice in 2 independent experiments on days 15 and 30 post tumor
injection.
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time points, parenchymal tdTom+ signals overlapped with the
FDC-marker CD35 and assumed the same dendritic shape as FDC
by immunofluorescence and 2PM analysis. Third, FDC, B cells,
and/or macrophages were required for tdTom+ signal accumula-
tion inside TDLNs. Finally, we were unable to recover tumor cells
from TDLNs, in contrast to the primary tumor site (not shown).
Taken together, we postulate that tdTom+ signals observed on
FDCs represent bona fide TDA and support the use of B16.F10-
tdTom cells as novel tool to quantitatively follow TDA deposition
in TDLNs.
Our combined 2PM and OPT analysis uncovered two relevant
aspects of TDA presentation, which have gone previously unno-
ticed: first, we show extensive scanning of FDC-deposited TDA by
circulating B cells. In our experimental setup, this scanning did not
induce significant slowing of B cells as is the case when cognate
Ag is encountered in inflamed LNs (20, 21). This is most likely
because the Ag-specific precursor frequency in our polyclonal B
cell population was too low to identify occasional responders. A
second central aspect is the OPT-based evaluation of TDA spread,
which showed that approximately 90% of FDC networks within B
cell follicles contained abundant TDA. This spread was not limited
to the first TDLN but spilled over to further LNs. In combination
with our observation of extensive B cell scanning of TDA-bearing
FDCs, it is likely that a sizeable percentage, if not the vast majority,
of the naïve B cell pool comes in direct contact with TDA during
the first weeks after tumor injection. This may explain the readily
detectable anti-TDA IgG levels in tumor-bearing mice.
Using 2PM imaging, we found that CX3CR1+ SCS
macrophages take up subcellular-sized particles containing a cyto-
plasmic fluorescent fusion protein produced by B16 melanoma
cells, which may represent apoptotic bodies from the primary
tumor site or tumor-derived microvesicles (49). A similar mech-
anism of apoptotic vesicle uptake has been described to involve
CD169+ macrophages with cross-presenting capacity for CD8+
T cell activation (23). Yet, the preservation of tdTom signal over
weeks suggests that not all engulfed TDA is cross-presented in our
model, but deposited and/or endocytosed as largely unprocessed
antigen on FDCs (37). It has to be kept in mind that our
study does not address whether TDA travels freely from primary
tumors via afferent lymph or is transported by CX3CR1− DCs or
macrophage subsets. In any case, our data extend the functions
of SCS macrophages to not only induce T cell responses but also
to capture Ag for presentation to B cells. In fact, this process has
been shown to occur frequently during viral infections, and has
been associated with non-specific B cell capture of immune com-
plexes as shuttle from macrophages to FDCs (25). Along this line,
we observed a lack of TDA capture in MD4 LNs, suggesting a role
for immune complexes for TDA relay to FDCs. In a recent study,
SCS macrophage depletion resulted in blunted B cell responses in
draining LNs, owing to defective antigen capture (50). While we
have not specifically addressed this issue in our study, it is likely
that CLL treatment prevents B cell activation in TDLNs in a similar
fashion. Under these conditions, TDA may then be further drained
by lymphatic vessels, until it becomes deposited by mechanisms
independent of macrophage capture, e.g., by DC subsets. Thus,
CLL treatment may simply alter the site of antibody production,
rather than suppress humoral responses, as has been shown in a
viral infection model (24). Future experiments using adoptively
transferred BCR-transgenic B cells and appropriate tumor anti-
gens need to be performed to shed light on this important aspect.
In sum, our microscopic and whole-mount data uncover a pre-
viously unnoticed widespread macrophage-mediated TDA depo-
sition on FDC in the B16.F10 model, using an intrinsically fluo-
rescent fusion protein as surrogate TDA. Extensive TDA scanning
by naïve B cells correlated with anti-TDA IgG production. More
than 20 years ago, TDA deposition on FDC has been reported in
TDLNs of colon carcinoma patients (51), which we confirm here
in TLDNs of melanoma patients. In future studies, we will expand
the panel of tumor antigens to generate a comprehensive map of
the TDA, which are most frequently associated with B cell follicles
in melanoma patients. Such data may be useful in future anticancer
immunotherapies, in particular since recent patient studies have
shown that the abundance of immune cells governing humoral
responses positively correlates with good prognosis (10, 11).
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at
http://www.frontiersin.org/Journal/10.3389/fimmu.2015.00114/
abstract
Figure S1 | MelA deposition in B cell follicles ofTDLNs taken from human
melanoma patients. (A–C) Immunofluorescent analysis of CD20, MelA, and
DAPI signals in TDLNs from human melanoma patients. In (B,C), representative
MelA+ positive signals associated with B cell follicles are marked by arrows,
while in (A), arrows point to MelA− B cell follicles. Scale bar, 100µm. Sections
are representative of five sections from three donors.
Figure S2 | Experimental schemes for 2PM and whole-mount LN imaging.
(A) Scheme for 2PM experiments. (B) Scheme for 3D whole-mount
quantification of TDA deposition. (C) Scheme for macrophage depletion
experiments using control and clodronate liposomes.
Movie S1 | 2PM image sequence of tdTom+ structures below SCS of
TDLNs. tdTom+ structures (red) in close proximity to SCS macrophages
(green-blue). Co-localization of tdTom+ and LYVE-1+ signal (green) appears
yellow. Time in minutes and seconds.
Movie S2 | High-resolution image sequence of dendritic tdTom+ structure
inTDLNs. tdTom+ structures (red; arrows) in close proximity to macrophages
(green-blue) show dendritic morphology. Scale bar, 20µm; time in minutes and
seconds.
Movie S3 | tdTom+ structure scanning by naïve B cells. tdTom+ structures
(red) in close proximity to macrophages (green) are scanned by naïve B cells
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(blue) within TDLNs. Representative B cell tracks are shown in white, while
arrows show immobile macrophages for comparison. Scale bar, 30µm; time in
minutes and seconds.
Movie S4 | tdTom+ structure scanning by naïve B cells. tdTom+ structures
(red) in close proximity to macrophages (green) are scanned by naïve B cells
(blue) within TDLNs. To highlight interactions, the image sequence is kept in 3D
mode and zooms into a tdTom+-rich region. Time in minutes and seconds.
Movie S5 | OPT reconstruction of tdTom+ structure inTDLNs. tdTom+
structures (red) are concentrated around the periphery of TDLN (autofluorescent
signal in blue). Scale bar, 400µm.
Movie S6 | tdTom+ fragment retention in SCS ofTDLNs. tdTom+ particles
(red) localize inside (arrow) or in close proximity (arrowhead) of CX3CR1+ SCS
macrophages (green) located below the collagen fibers (blue) of the TDLN
capsule. Scale bar, 20µm; time in minutes and seconds.
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